SAM
AVDL

Senzar Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Senzar Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-441,500
Closed -$5.39M – 38
2015
Q4 		$5.39M Buy
+441,500
New +$6.88M 0.6% 32
2015
Q2 		– Sell
-225,351
Closed -$4.05M – 39
2015
Q1 		$4.05M Buy
+225,351
New +$3.53M 0.99% 25

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return
FPC
Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Senzar Asset Management's AVDL Position: Q1 2016 in Review

Senzar Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2016, closing a stake of 441,500 shares — an estimated $5.39M sold.

Senzar Asset Management first reported a position in AVDL in Q1 2015 and held it in 2 quarters. The position peaked at $5.39M in Q4 2015. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2016.

  • Senzar Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Senzar Asset Management sold 441,500 Avadel Pharmaceuticals shares in Q1 2016, an estimated $5.39M.
  • Senzar Asset Management first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Senzar Asset Management's Avadel Pharmaceuticals position peaked at $5.39M in Q4 2015.
  • 81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2016.

Based on Senzar Asset Management's 13F filing for Q1 2016, filed 13 May 2016.